Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Armistice Capital
AddedFeb 19, 2024
UpdatedJun 28, 2026
Armistice Capital

Armistice Capital

Operating

Global hedge fund specializing in healthcare and consumer sectors.

Location
New York City, NY, US
Founded
2012
Firm
Compare
Portfolio
Employees
Website

Armistice Capital is a global hedge fund specializing in long/short, value-oriented, and event-driven strategies. The firm primarily focuses on the healthcare and consumer sectors, leveraging its expertise to identify investment opportunities. Armistice Capital's approach combines thorough research with a keen understanding of market dynamics to generate returns for its investors.

The fund has made notable investments in several biotechnology and pharmaceutical companies, including 2seventy bio, Abeona Therapeutics, and Karyopharm Therapeutics. Armistice Capital typically engages in post-IPO equity rounds, demonstrating its commitment to supporting companies in their growth stages. The firm's portfolio reflects a strong emphasis on innovative therapies and cutting-edge medical technologies.

Armistice Capital - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments10
Current Portfolio Count10
Total Portfolio Exits0

Top Investment Stages

Post Ipo Equity10 (100.0%)

Stage Mix

Post Ipo Equity 100%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Outlook Therapeutics logo

Outlook Therapeutics

Aligos Therapeutics logo

Aligos Therapeutics

Lyra Therapeutics logo

Lyra Therapeutics

Spruce Biosciences logo

Spruce Biosciences

Karyopharm Therapeutics logo

Karyopharm Therapeutics

Abeona Therapeutics logo

Abeona Therapeutics

2seventy bio logo

2seventy bio

Hyperion DeFi logo

Hyperion DeFi

Xeris Biopharma Holdings logo

Xeris Biopharma Holdings

Kiora Pharmaceuticals logo

Kiora Pharmaceuticals

Armistice Capital - Similar Investment Firms

ArmaVir Partners logo

ArmaVir Partners

Armentum Partners logo

Armentum Partners

Armyn Capital logo

Armyn Capital

armyn.capital

Amicus Capital Partners logo

Amicus Capital Partners

Amherst Fund logo

Amherst Fund

Health2047 Capital Partners logo

Health2047 Capital Partners

Ridgeback Capital logo

Ridgeback Capital

ridgebackcm.com

Ante Capital logo

Ante Capital

SilverArc Capital logo

SilverArc Capital

Altium Capital logo

Altium Capital

altiumcap.com

Arsenal Capital Partners logo

Arsenal Capital Partners

arsenalcapital.com

Aspire Capital Partners logo

Aspire Capital Partners

aspirecapital.com

Armory Square Ventures logo

Armory Square Ventures

armorysv.com

Plaisance Capital Management logo

Plaisance Capital Management

plaisancecap.com

Mirae Asset Capital Life Science logo

Mirae Asset Capital Life Science

Armistice Capital - Classification

Also Known As
  • Armistice Capital, LLC
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
Show 2 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
SIC
  • 6000Depository Institutions